Want to join the conversation?
$BAX paid approx. $14MM to acquire the rights to cefazolin injection in GALAXY Container (2 g/100 mL) in 3Q15. The purchase price was capitalized as an intangible asset and $BAX is amortizing the asset over the estimated economic life. In the Other franchise, sales fell mainly due to one of $BAX's pharma partners assuming their own production.
$JNJ down 2% in pre-market trading. Earnings beat expectations, but sales disappointed. Johnson is cautious on its outlook. How it will perform in the future?
$YHOO is reporting today after market close. Nobody cares about this stock.
$WBA is yet to receive US anti-trust clearance for its Rite Aid acquisition. The deadline for the deal expires on January 27.